Measurement of phosphorylated tau protein in blood plasma allows Alzheimer’s disease to be distinguished from other neurological diseases and may assist in disease detection during the prodromal stage.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease
Scientific Reports Open Access 05 August 2021
-
The informed road map to prevention of Alzheimer Disease: A call to arms
Molecular Neurodegeneration Open Access 21 July 2021
-
Requirement of brain interleukin33 for aquaporin4 expression in astrocytes and glymphatic drainage of abnormal tau
Molecular Psychiatry Open Access 12 January 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bateman, R. J. et al. N. Engl. J. Med. 367, 795–804 (2012).
Janelidze, S. et al. Nat. Med. https://doi.org/10.1038/s41591-020-0755-1 (2020).
Thijssen, E. H. et al. Nat. Med. https://doi.org/10.1038/s41591-020-0762-2 (2020).
Sato, C. et al. Neuron 97, 1284–1298.e7 (2018).
Barthélemy, N. R., Horie, K., Sato, C. & Bateman, R. J. J. Prev. Alzheimers Dis. 6, S34–S35 (2019).
Barthélemy, N. R., Mallipeddi, N., Moiseyev, P., Sato, C. & Bateman, R. J. Front. Aging Neurosci. 11, 121 (2019).
Nakamura, A. et al. Nature 554, 249–254 (2018).
Ovod, V. et al. Alzheimers Dement. 13, 841–849 (2017).
Schindler, S. E. et al. Neurology 93, e1647–e1659 (2019).
Preische, O. et al. Nat. Med. 25, 277–283 (2019).
Mielke, M. M. et al. Alzheimers Dement. 14, 989–997 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (blood plasma assay) licensed by Washington University to C2N Diagnostics, and R.J.B. receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University has submitted the US provisional patent application ‘Plasma Based Methods for Detecting CNS Amyloid Deposition’ (co-inventor, R.J.B.) and the US non-provisional patent application ‘Methods of Diagnosing and Treating Based on Site-Specific Tau Phosphorylation’ (co-inventors, R.J.B. and N.R.B.).
Rights and permissions
About this article
Cite this article
Bateman, R.J., Barthélemy, N.R. & Horie, K. Another step forward in blood-based diagnostics for Alzheimer’s disease. Nat Med 26, 314–316 (2020). https://doi.org/10.1038/s41591-020-0797-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-0797-4
This article is cited by
-
Investigating the relationship between mild traumatic brain injury and Alzheimer’s disease and related dementias: a systematic review
Journal of Neurology (2022)
-
The informed road map to prevention of Alzheimer Disease: A call to arms
Molecular Neurodegeneration (2021)
-
Novel blood test for early biomarkers of preeclampsia and Alzheimer’s disease
Scientific Reports (2021)
-
Requirement of brain interleukin33 for aquaporin4 expression in astrocytes and glymphatic drainage of abnormal tau
Molecular Psychiatry (2021)
